WO2023022490A1 - 폴리 a 테일을 안정적으로 유지하는 방법 - Google Patents
폴리 a 테일을 안정적으로 유지하는 방법 Download PDFInfo
- Publication number
- WO2023022490A1 WO2023022490A1 PCT/KR2022/012233 KR2022012233W WO2023022490A1 WO 2023022490 A1 WO2023022490 A1 WO 2023022490A1 KR 2022012233 W KR2022012233 W KR 2022012233W WO 2023022490 A1 WO2023022490 A1 WO 2023022490A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- poly
- tail
- cell line
- culturing
- plasmid
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 66
- 239000013612 plasmid Substances 0.000 claims description 87
- 238000012258 culturing Methods 0.000 claims description 48
- 108020004999 messenger RNA Proteins 0.000 claims description 36
- 241000588724 Escherichia coli Species 0.000 claims description 32
- 230000009466 transformation Effects 0.000 claims description 28
- 108091036407 Polyadenylation Proteins 0.000 claims description 22
- 239000007787 solid Substances 0.000 claims description 21
- 239000007788 liquid Substances 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 13
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 10
- 230000035939 shock Effects 0.000 claims description 10
- 238000013518 transcription Methods 0.000 claims description 9
- 230000035897 transcription Effects 0.000 claims description 9
- 238000011084 recovery Methods 0.000 claims description 8
- 238000004520 electroporation Methods 0.000 claims description 5
- 210000004027 cell Anatomy 0.000 description 67
- 108091034057 RNA (poly(A)) Proteins 0.000 description 42
- 239000002609 medium Substances 0.000 description 36
- 108020004414 DNA Proteins 0.000 description 16
- 238000010367 cloning Methods 0.000 description 16
- 239000012634 fragment Substances 0.000 description 16
- 230000000052 comparative effect Effects 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 238000012163 sequencing technique Methods 0.000 description 9
- 238000012790 confirmation Methods 0.000 description 8
- 238000007480 sanger sequencing Methods 0.000 description 8
- 238000011534 incubation Methods 0.000 description 7
- 239000003814 drug Substances 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 238000009630 liquid culture Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 229930024421 Adenine Natural products 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 229960000643 adenine Drugs 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 108700021021 mRNA Vaccine Proteins 0.000 description 4
- 229940126582 mRNA vaccine Drugs 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000006152 selective media Substances 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 238000011426 transformation method Methods 0.000 description 2
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 102000001218 Rec A Recombinases Human genes 0.000 description 1
- 108010055016 Rec A Recombinases Proteins 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical group C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- -1 for example Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- HBMJWWWQQXIZIP-UHFFFAOYSA-N silicon carbide Chemical compound [Si+]#[C-] HBMJWWWQQXIZIP-UHFFFAOYSA-N 0.000 description 1
- 229910010271 silicon carbide Inorganic materials 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
- C12N15/68—Stabilisation of the vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
- C12N15/69—Increasing the copy number of the vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Definitions
- the present invention relates to a method for stably maintaining a poly A tail.
- mRNA has recently been attracting attention as an active pharmaceutical ingredient (API) of pharmaceuticals.
- mRNA requires a component called poly(A) tail, which plays an important role in RNA stability and translation.
- poly(A) tail In the case of mRNA constituting an mRNA vaccine, 120 poly A tails are recognized as a standard size (Mol Ther Nucleic Acids. 2021 Dec 3;26:945-956).
- PolyA signal is present in the mRNA transcribed in the cell, and a polyA tail is added after the transcription process.
- Poly A tails are also required to increase in vivo stability and translation efficiency even in mRNA produced by in vitro transcription (IVT).
- One method is to synthesize a poly A tail using polyA polymerase after IVT, and the other method is to include an adenine repeat sequence in the template used for IVT to generate a poly A tail through IVT. am.
- An object of the present invention relates to a method for stably maintaining a poly A tail.
- the present invention provides a method for stably maintaining a poly A tail.
- the poly A tail can be easily cloned and the poly A sequence can be stably maintained.
- Figure 1 confirms the colony PCR results upon cloning of poly(A) sequences using DH5alpha at 37 degrees Celsius.
- Figure 2 confirms the colony PCR results upon cloning of the poly(A) sequence using Stbl3 at 37 degrees Celsius.
- Figure 4 is a graph showing the results of comparing the A124 ⁇ 1 ratio when a cell line transformed with a plasmid containing a sequence encoding a poly(A) tail is cultured under various temperature conditions.
- Figure 5 is a graph showing the results of culture curves for each temperature obtained by measuring OD600 at a given time while incubating the prepared stock at 200 rpm for 48 hours at 13, 16, 19, 22, and 25 degrees.
- One embodiment of the present invention is a method for stably maintaining a poly A tail in a plasmid.
- the method includes culturing a cell line transformed with a plasmid containing a sequence encoding a poly(A) tail at a temperature of 31 °C or less.
- the culturing step includes (1) restoring the cell line to a temperature condition of 31 °C or less.
- the method includes, after the recovery step of (1), (2) culturing the cell line in a solid medium at a temperature of 31 ° C or less to form colonies.
- the culturing further comprises (3) culturing the colonies formed by the solid medium culture in (2) in a liquid medium at a temperature of 31 ° C or less.
- the method comprises (1) restoring a cell line transformed with a plasmid comprising a sequence encoding a poly A tail to a temperature condition of 31 ° C. or less; (2) forming colonies through solid culture of the recovered cell line at a temperature of 31 ° C or lower; and (3) performing liquid culture at a temperature of 31 °C or less.
- the culturing in the liquid medium includes subculturing.
- the temperature conditions in steps (1) to (3) are 16°C to 31°C.
- the temperature conditions in steps (1) to (3) are 19°C to 25°C.
- the cell line is E.coli.
- the transformation includes introducing a plasmid containing a poly A tail-encoding sequence into a cell line using heat shock or electroporation.
- the introduction is performed at a temperature of 37 °C to 42 °C.
- the method further comprises preserving the cultured cell line.
- the preserving step comprises freezing and/or drying the cell line.
- the culturing comprises culturing and activating the conserved strain.
- the method is characterized in that the stability of the poly A tail in the plasmid is increased compared to a method comprising culturing the cell line transformed with the plasmid at a temperature of 37 ° C. or higher.
- the poly A tail comprises 20 to 400 adenine (A) atoms.
- Another aspect embodying the present invention is a method for mass production of plasmids for mRNA production.
- the method comprises culturing a cell line transformed with a plasmid containing a sequence encoding mRNA including a poly(A) tail at a temperature condition of 31 ° C. or less. .
- the mRNA is a component of an immunogenic composition and/or therapeutic agent.
- Another aspect embodying the present invention is a method for producing mRNA containing a poly A tail.
- the method comprises culturing a cell line transformed with a plasmid containing a sequence encoding an mRNA containing a poly(A) tail at a temperature of 31 ° C. or less. .
- the method comprises recovering the plasmid from the cell line and performing transcription in vitro.
- the mRNA is a component of an immunogenic composition and/or therapeutic agent.
- One aspect of the invention is a method for stably maintaining a poly A tail in a plasmid.
- the method includes culturing a cell line transformed with a plasmid containing a sequence encoding a poly(A) tail at a temperature of 31° C. or less.
- poly A tail refers to a contiguous or discontinuous sequence of adenylate residues typically located at the 3' end of an RNA molecule.
- a poly A tail may follow the 3' of the mRNA, for example the 3'UTR.
- Such poly A tails may consist of or include about 20 or more, 25 or more, 40 or more, 60 or more, 80 or more, or 100 or more adenyl (A) nucleotides.
- the poly A tail may include 20 to 400 adenine (A) atoms.
- A adenine
- 20 to 300, 40 to 200, 50 to 190, 60 to 180, 70 to 170, 60 to 160, 70 to 150, or 80 to 140 adenines may be included. Examples may include, but are not limited to, about 120 adenines.
- the poly A tail may contain modifications that delay the degradation of mRNA.
- a plasmid containing a poly A tail includes a promoter capable of initiating transcription, an arbitrary operator sequence for regulating such transcription, a sequence encoding a target mRNA, and a sequence regulating termination of transcription and translation. can do.
- the plasmid may include a restriction enzyme binding site that is easy to utilize for cloning.
- the plasmid may include a selection marker for determining whether or not transformation occurs.
- Markers conferring selectable phenotypes such as drug resistance, auxotrophy, and resistance to cytotoxic agents can be used, and only cells expressing the selectable marker survive or exhibit other phenotypes in the environment treated with the selective agent. Therefore, transformed cells can be selected.
- it is not limited to the above examples.
- the plasmid of the present invention can be prepared by introducing a sequence encoding the poly A tail into the plasmid.
- the sequence encoding the poly A tail is amplified by PCR, treated with a restriction enzyme, and then ligated with the plasmid treated with the restriction enzyme to obtain a plasmid containing the sequence encoding the poly(A) tail can prepare
- a polynucleotide sequence encoding mRNA may be linked to the upper end of the sequence encoding the poly A tail.
- the plasmid may be used as a template for transcribing a target mRNA containing a polynucleotide sequence encoding an mRNA at the top of a sequence encoding a poly A tail.
- a cell line transformed with a plasmid containing the sequence encoding the poly(A) tail of the present invention can be prepared by introducing a plasmid containing the sequence encoding the poly A tail into the cell line. .
- introducing a plasmid containing a sequence encoding the poly A tail into a cell line may also be referred to as transforming the cell line with the plasmid.
- transduction or “transformation” of a plasmid means transfer of the plasmid to a cell line. Such introduction can be easily performed according to a conventional method in the art.
- cells may be treated to be permeable to DNA molecules, and cells that have undergone this process are referred to as competent cells.
- the introduction may be performed using heat shock or electroporation.
- Plasmid delivery using heat shock is accomplished by mixing DNA and cells and applying heat momentarily.
- the introduction by thermal shock may be performed at a temperature condition of about 37° C. or higher, and specifically, at a temperature condition of about 37° C. to 42° C. Cooling the cells on ice before and/or after heat shocking may be included.
- Electroporation is a method of delivering plasmids using electricity.
- a short, high-voltage electrical pulse stimulus is applied to change the membrane potential of the cell membrane, nanometer-sized pores are created on the surface of the cell membrane to increase DNA permeability.
- the introduction by electroporation may be performed at a temperature condition of about 37° C. or higher, and specifically, at a temperature condition of about 37° C. to 42° C. Chilling the cells on ice before and/or after application of electrical stimulation may be included.
- the CaCl 2 precipitation method the Hanahan method with increased efficiency by using a reducing material called DMSO (dimethyl sulfoxide) in the CaCl 2 method
- DMSO dimethyl sulfoxide
- calcium phosphate precipitation method calcium phosphate precipitation method
- protoplast fusion method stirring method using silicon carbide fibers
- stirring method using silicon carbide fibers characterization using PEG transformation methods, dextran sulfate, lipofectamine and desiccation/inhibition mediated transformation methods and the like
- a poly A tail is stably required for mRNA stability and translation efficiency, and the present applicant has stably cloned the poly A tail encoding sequence newly present in the plasmid without loss. and a method for culturing E. coli cloned in a method capable of mass production and maintenance.
- the step of culturing the cell line into which the plasmid containing the sequence encoding the poly A tail has been introduced at a temperature of 31 ° C. or lower may include any one or more of the following steps:
- the (i) step of recovering the cell line is a step of culturing the cell line, which was in a competent state after transformation, in a medium to recover physiological functions.
- the medium in the recovery step may be a non-selective medium.
- the culture temperature in the recovery step is about 31 ° C or less, for example, about 16 ° C to 31 ° C, about 16 ° C to 30 ° C, about 16 ° C to 29 ° C, about 16 ° C to 28 ° C, about 16 ° C to 27 °C, about 16 °C to 26 °C, about 16 °C to 25 °C, about 17 °C to 25 °C, about 18 °C to 25 °C, or about 19 °C to 25 °C.
- the culture time in the recovery step may be about 5 minutes to 2 hours.
- Colonies may be formed by culturing the transformed cell line through the step (ii) culturing the cell line in a solid medium.
- Colony means a population of cell lines into which a plasmid of interest has been introduced.
- Solid medium may also be referred to as "solid medium”.
- solid medium culture it is possible to check the growth of the strain and the introduction of the plasmid, and a selective medium can be used to check the introduction of the plasmid.
- the selective medium may contain antibiotics.
- the temperature of the culturing in the solid medium is about 31 ° C or less, for example, about 16 ° C to 31 ° C, about 16 ° C to 30 ° C, about 16 ° C to 29 ° C, about 16 ° C to 28 ° C, about 16 °C to 27 °C, about 16 °C to 26 °C, about 16 °C to 25 °C, about 17 °C to 25 °C, about 18 °C to 25 °C, or about 19 °C to 25 °C.
- Mass culture of the cell line is possible through the step (iii) culturing the cell line in a liquid medium.
- the culturing in the liquid medium may be culturing a single colony obtained in the solid medium culturing step of (ii).
- the temperature of the culturing in the liquid medium is about 31 ° C or less, for example, about 16 ° C to 31 ° C, about 16 ° C to 30 ° C, about 16 ° C to 29 ° C, about 16 ° C to 28 ° C, about 16 °C to 27 °C, about 16 °C to 26 °C, or about 16 °C to 25 °C, about 17 °C to 25 °C, about 18 °C to 25 °C, or about 19 °C to 25 °C.
- culturing in the liquid medium may include subculturing.
- Subculture means that some cells from the original culture are transplanted into a new medium and newly cultured.
- Cell density can be appropriately controlled through subculture.
- the subculture may be performed 2 or 3 times, or more, but is not limited thereto and can be appropriately adjusted by those skilled in the art.
- the method of the present invention may further include preserving the cultured cell line.
- the preserving step includes freezing and/or drying the cell line.
- cryoprotectant for example, materials known in the art such as glycerol or dimethylsulfoxide may be used.
- the culturing comprises culturing and activating the conserved strain.
- Preserved strains may be frozen or dried.
- Culture in the activating step may be solid culture or liquid culture.
- the poly A tail in the plasmid can be stably maintained in the step of preserving and activating the cultured cell line.
- the medium used in the culturing step of the present invention may contain nutrients required for culturing the cell line.
- a conventional medium containing a carbon source, nitrogen source, phosphorus, inorganic compound, amino acid, and/or vitamin may be used.
- compounds such as ammonium hydroxide, potassium hydroxide, ammonia, phosphoric acid, sulfuric acid and the like may be added to the medium in an appropriate manner to adjust the pH of the medium.
- the cell line of the present invention is not particularly limited, but may be E.coli.
- E. coli is a host cell widely used for mass production or cloning of DNA, and the cell line of the present invention may include wild-type E. coli as well as mutant E. coli engineered to have characteristics advantageous to cloning.
- a strain in which RecA is deleted may be used. However, it is not limited thereto.
- the length of the poly A tail included in the plasmid may be shortened due to recombination or deletion in the cell line. However, when cells are cultured by the method of the present invention, the length of the poly A tail included in the plasmid can be stably maintained.
- the method is characterized in that the stability of the poly A tail in the plasmid is increased compared to a method comprising culturing a cell line into which the plasmid is introduced at a temperature of 37° C. or higher.
- the culturing may include one or more of (i) recovering the cell line, (ii) culturing the cell line in a solid medium, and (iii) culturing the cell line in a liquid medium.
- Another aspect of the present invention is a method for mass production of a plasmid for mRNA production.
- the method includes culturing a cell line transformed with a plasmid containing an mRNA encoding sequence including a poly(A) tail at a temperature of 31° C. or less.
- Poly(A) tail, plasmid, cell line, culture and temperature conditions are as described above.
- the produced plasmid can be used as a template for synthesizing mRNA in vitro.
- the method may further include recovering the plasmid from the cell.
- it is not limited thereto.
- mRNA containing a poly A tail synthesized using the plasmid as a template may be used as one component of an immunogenic composition.
- mRNA containing a poly A tail synthesized using the plasmid as a template can be used as a component of a therapeutic agent.
- Another aspect of the present invention is a method for producing mRNA.
- the method comprises the steps of culturing a cell line transformed with a plasmid containing a sequence encoding an mRNA containing a poly(A) tail at a temperature of 31 ° C. or less; and performing transcription using the plasmid of the cell line as a template.
- the poly (A) tail and mRNA containing the tail, plasmid, cell line, culture and temperature conditions are the same as described above.
- the plasmid may be recovered from the cell line.
- the transcription step may be performed in vitro.
- the production method may further include formulating the produced mRNA.
- diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants may be used.
- the preparation method may include preparing mRNA in a form included in lipid nanoparticles. However, it is not limited thereto.
- the mRNA containing the poly A tail produced above may be used as one component of an immunogenic composition.
- the mRNA containing the poly A tail produced above can be used as a component of a therapeutic agent.
- DNA oligos consisting of sequences of SEQ ID NO: 1 and SEQ ID NO: 2 (made to order by Cosmogenetech) were mixed at a 1:1 molar ratio and heated at 95 degrees to -1 degrees per minute. was lowered and annealed, and a double-stranded polyA DNA fragment was prepared by filling the gap with Klenow large fragment (NEB). Then, after digestion with restriction enzymes SacII and HindIII (NEB), using T4 DNA ligase, the zygote was prepared by inserting it into the plasmid (pSKBS01, SEQ ID NO: 3) digested with the same restriction enzyme.
- the prepared zygote was transformed into E. coli DH5alpha (Enzynomics, CP010).
- the zygote was placed in E. coli for transformation on ice, allowed to stand for 30 minutes, and then subjected to heat shock at 42 degrees Celsius for 30 seconds. After cooling on ice for 2 minutes, SOC medium was added, and after recovery at 37 ° C. for 1 hour, E. coli was smeared on antibiotic-selective solid medium.
- the culture medium on which E. coli was smeared was cultured at 37 degrees Celsius to form colonies.
- the colonies formed on the selective medium after transformation are subjected to colony PCR to determine whether the poly(A) fragment can be inserted, and then plasmids are isolated from colonies in which the possibility of inserting the fragment is confirmed, and the inserted sequence is analyzed through nucleotide sequence analysis. confirmed.
- M13-Forward and M13-Reverse primers (SEQ ID NOs: 4 and 5) were used.
- a PCR product with a size of 550 bp was generated, and in the case of a plasmid that was not inserted, a size of 446 bp. was created.
- PCR was performed on 40 colonies, and the PCR product was confirmed on an agarose gel.
- 19 clearly showed 446 bp, indicating that poly(A) was not inserted.
- the remaining 21 showed a multiband pattern, but contained a PCR product with a size of 550 bp (Fig. 1).
- plasmids were isolated from these 21 cells for which fragment insertability was confirmed, and sequencing was performed using Sanger sequencing.
- the Stbl3 strain one of strains specialized for cloning unstable fragments including repetitive sequences, was used. During transformation, the incubation temperature was 37 degrees Celsius as in Comparative Example 1 above.
- the conjugate prepared in Comparative Example 1 was transformed into E. coli Stbl3 (Invitrogen, C737303).
- the zygote was placed in E. coli for transformation on ice, allowed to stand for 30 minutes, and then subjected to heat shock at 42 degrees Celsius for 42 seconds. After cooling on ice for 2 minutes, SOC medium was added, and after recovery at 37 ° C. for 1 hour, E. coli was smeared on antibiotic-selective solid medium.
- the culture medium on which E. coli was smeared was cultured at 37 degrees Celsius to form colonies.
- Colony PCR was performed in the same manner as in Comparative Example 1. PCR was performed on 25 colonies and the PCR product was confirmed on an agarose gel. Seventeen clearly showed 446 bp, indicating that poly(A) was not inserted. The remaining 8 showed a multiband pattern, but contained a PCR product with a size of 550 bp (Fig. 2). After liquid culture at 37 degrees Celsius, plasmids were isolated from these 8 cells for which fragment insertability was confirmed, and sequencing was performed using Sanger sequencing.
- the conjugate prepared in Comparative Example 1 was transformed into E. coli DH5alpha (Enzynomics, CP010) and Stbl3 (Invitrogen, C737303), respectively. Except for the E. coli culture temperature, other conditions were the same as those mentioned in Comparative Examples 1 and 2. E. coli was recovered at 25 degrees Celsius after heat shock, and colonies were formed by plating E. coli on antibiotic-selective solid medium and culturing at 25 degrees Celsius.
- Colony PCR was performed in the same manner as in Comparative Example 1. PCR was performed on 10 colonies per each strain, and the PCR product was confirmed on an agarose gel.
- poly(A) tail In order to explore the temperature range in which the poly(A) tail can be stably maintained, plasmid DNA containing the poly(A) tail is transformed and cultured in liquid under various temperature conditions, and their nucleotide sequences are analyzed to obtain poly(A) tail. (A) It was confirmed that the tail was maintained.
- Plasmid DNA with a poly(A) tail length of 124 was prepared using the method described above (Comparative Example 1), and the plasmid DNA was transformed into E. coli DH5alpha (Enzynomics, CP010). Plasmid DNA was added to E. coli, left on ice for 30 minutes, and then subjected to heat shock at 42 degrees Celsius for 40 seconds. After cooling on ice for 2 minutes, SOC medium was added and incubated for 1 hour at 37 degrees, 34 degrees, 32 degrees, 31 degrees, 28 degrees, 25 degrees, 22 degrees, and 19 degrees Celsius, respectively. Escherichia coli was smeared. The culture medium on which E. coli was smeared was cultured at the same temperature as the temperature at which E. coli was recovered to form colonies.
- plasmids for sequencing 24 or 25 colonies generated on the solid medium were selected and cultured in liquid at the same temperature as the solid medium. After liquid culture, the plasmid was isolated and the poly(A) sequence length and base sequence were analyzed using Sanger sequencing. Atail-seq-R (SEQ ID NO: 6) primer was used for sequencing.
- NEB stable strain which is one of the strains specialized for maintaining unstable fragments, to check whether the poly(A) sequence can be maintained intact during continuous subculture under low temperature conditions proceeded.
- the plasmid DNA used in Example 2 was transformed into E. coli NEB stable (NEB, C3040H). Plasmid DNA was added to E. coli for transformation on ice, allowed to stand for 30 minutes, and then subjected to heat shock at 42 degrees Celsius for 40 seconds. After cooling on ice for 5 minutes, NEB 10-beta/Stable Outgrowth medium was added, and after recovery at 37 degrees Celsius or 25 degrees Celsius for 1 hour, E. coli was plated on antibiotic-selective solid medium. The culture medium on which E. coli was smeared was cultured at the same temperature as the temperature at which E. coli was recovered to form colonies.
- E. coli NEB stable NEB, C3040H
- Plasmid DNA was added to E. coli for transformation on ice, allowed to stand for 30 minutes, and then subjected to heat shock at 42 degrees Celsius for 40 seconds. After cooling on ice for 5 minutes, NEB 10-beta/Stable Outgrowth medium was added, and after recovery at 37 degrees Celsius or 25 degrees
- the transformed cell line which was identified as having 124 A lengths in Example 3 at 25 degrees, was made into a glycerol stock form and stored in a -70 ° C freezer. kept.
- the stocks stored in a frozen state were taken out and liquid cultured in different test tubes at 16 degrees, 25 degrees, and 30 degrees, and then each plasmid was separated and sequenced.
- a total of 124 A lengths were analyzed in the plasmid isolated from cultured E. coli, and it was confirmed that the A length was maintained intact during culture after stock preparation.
- Stock culture# A length by incubation temperature 16 degrees 25 degrees 30 degrees One 124 124 124 2 124 124 124 3 124 124 124 4 124 124 124 5 124 124 124 6 124 124 124 124
- the transformed cell lines DH5alpha and NEB stable which were confirmed to have 124 A lengths at 25 degrees, were each made into glycerol stocks and stored in a -70 ° C freezer.
- the stock was taken out and cultured at 200 rpm for 48 hours at 13, 16, 19, 22, and 25 degrees, and the OD 600 was measured at a fixed time. As a result of the experiment, it was confirmed that there was almost no cell growth at 13 degrees below 16 degrees (FIG. 5).
Landscapes
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
콜로니# | 형질전환 및 배양온도 | |||||||
19℃ | 22℃ | 25℃ | 28℃ | 31℃ | 32℃ | 34℃ | 37℃ | |
1 | n/a | 123 | 121 | 26 | 123 | 19 | 19 | 19 |
2 | 124 | 92 | 124 | 123 | 15 | 17 | 19 | n/a |
3 | 122 | 122 | 117 | 15 | 121 | 17 | 19 | 15 |
4 | 19 | 102 | 124 | n/a | 123 | 19 | 19 | 19 |
5 | 122 | 124 | 122 | 122 | 19 | 9 | 9 | 19 |
6 | 123 | 124 | 122 | 124 | 121 | 15 | n/a | 15 |
7 | n/a | 124 | 57 | 19 | 122 | 16 | 17 | 24 |
8 | n/a | 124 | 122 | 121 | 15 | 19 | 15 | 15 |
9 | 19 | 120 | 124 | 122 | 123 | 17 | n/a | 15 |
10 | 124 | 122 | 125 | 123 | 19 | 15 | 19 | 15 |
11 | 124 | 124 | 123 | 123 | 123 | n/a | 15 | 19 |
12 | 123 | 124 | 124 | 121 | 112 | 19 | 19 | 18 |
13 | 122 | 90 | 123 | 121 | 19 | 121 | 122 | 17 |
14 | n/a | 119 | 106 | 19 | 123 | 15 | 19 | 20 |
15 | 124 | 123 | 124 | 15 | 15 | n/a | 19 | 20 |
16 | 123 | 123 | 19 | 122 | 122 | n/a | 19 | 18 |
17 | 122 | 35 | 108 | 122 | 19 | 19 | n/a | 19 |
18 | 125 | 122 | 66 | 19 | 19 | n/a | n/a | 17 |
19 | 123 | 123 | 44 | 19 | 123 | 19 | 19 | 17 |
20 | 123 | 15 | 17 | 15 | 120 | 27 | 15 | 18 |
21 | 123 | 19 | 120 | 122 | 121 | n/a | n/a | 13 |
22 | n/a | 15 | 124 | 119 | 122 | n/a | n/a | 36 |
23 | 121 | 123 | 124 | 123 | 19 | 19 | 15 | 17 |
24 | 15 | n/a | 122 | 122 | 19 | n/a | n/a | 16 |
25 | 19 | 15 | n/a | n/a | 106 | n/a | 19 | n/a |
A124±1 비율 | 55.0% | 45.8% | 41.7% | 21.7% | 24.0% | 0.0% | 0.0% | 0.0% |
콜로니# | 배양온도 | |
섭씨 25도 | 섭씨 37도 | |
1 | 62 | 120 |
2 | 123 | 121 |
3 | 125 | 122 |
4 | 122 | 122 |
5 | 123 | 122 |
6 | 124 | 125 |
7 | 124 | 122 |
8 | 124 | 120 |
9 | 122 | 19 |
10 | 125 | 118 |
11 | 124 | 121 |
12 | 15 | 120 |
13 | 74 | 53 |
14 | 123 | 120 |
15 | 124 | 122 |
16 | 124 | 120 |
17 | 124 | 122 |
18 | 124 | 15 |
19 | 123 | 15 |
20 | 124 | 121 |
21 | 54 | 45 |
22 | 124 | 122 |
23 | 123 | 120 |
24 | 124 | 120 |
25 | 124 | 122 |
A124±1 비율 | 76.00% | 4.00% |
콜로니# | 배양온도 37도 | 1차 배양액의 A 길이 ±1 유지 |
||
1차 | 2차 | 3차 | ||
3 | 122 | 16 | 16 | X |
5 | 122 | 60 | 60 | X |
6 | 125 | 70 | n/a | X |
7 | 122 | 124 | 122 | O |
15 | 122 | 60 | 62 | X |
22 | 122 | 123 | 122 | O |
콜로니# | 배양온도25도 | 1차 배양액의 A 길이 ±1 유지 |
|||
1차 | 2차 | 3차 | 4차 | ||
3 | 125 | 125 | 125 | 125 | O |
5 | 123 | 123 | 122 | 122 | O |
7 | 124 | 124 | 124 | 124 | O |
9 | 122 | 122 | 122 | 121 | O |
11 | 124 | 124 | 124 | 124 | O |
15 | 124 | 124 | 123 | 123 | O |
17 | 124 | 124 | 124 | 123 | O |
19 | 123 | 123 | 123 | 123 | O |
23 | 123 | 123 | 123 | 123 | O |
스탁배양# | 배양온도별 A 길이 | ||
16도 | 25도 | 30도 | |
1 | 124 | 124 | 124 |
2 | 124 | 124 | 124 |
3 | 124 | 124 | 124 |
4 | 124 | 124 | 124 |
5 | 124 | 124 | 124 |
6 | 124 | 124 | 124 |
Claims (14)
- 폴리 A 테일 (poly(A) tail) 을 코딩하는 서열이 포함된 플라스미드로 형질전환된 세포주를 31 ℃ 이하의 온도 조건에서 배양하는 단계를 포함하는,폴리 A 테일을 플라스미드에서 안정적으로 유지하는 방법.
- 제1항에 있어서, 상기 배양하는 단계는 (1) 상기 세포주를 31 ℃ 이하의 온도 조건으로 회복시키는 것을 포함하는, 방법.
- 제2항에 있어서, 상기 (1)의 회복 단계 이후 (2) 상기 세포주를 31 ℃ 이하의 온도 조건으로 고체 배지에서 배양하여 콜로니를 형성하는 것을 포함하는, 방법.
- 제3항에 있어서, 상기 배양은 (3) 상기 (2) 의 고체 배지 배양으로 형성된 콜로니를 31 ℃ 이하의 온도 조건으로 액체 배지에서 배양하는 단계를 더 포함하는, 방법.
- 제4항에 있어서, 상기 액체 배지에서 배양하는 단계는 계대배양하는 것을 포함하는, 방법.
- 제1항 내지 제4항 중 어느 한 항에 있어서, 상기 온도 조건은 16 ℃내지 31 ℃인, 방법.
- 제1항 내지 제4항 중 어느 한 항에 있어서, 상기 온도 조건은 19 ℃내지 25 ℃인, 방법.
- 제1항에 있어서, 상기 세포주는 대장균(E. coli)인, 방법.
- 제1항에 있어서, 상기 형질전환은 열충격(heat shock) 또는 전기천공(electroporation)을 이용해 폴리 A 테일을 코딩하는 서열을 포함하는 플라스미드를 세포주에 도입하는 것을 포함하는, 방법.
- 제9항에 있어서, 상기 도입은 37 ℃ 내지 42 ℃의 온도에서 수행되는, 방법.
- 제1항에 있어서, 상기 방법은 폴리 A 테일 (poly(A) tail) 을 코딩하는 서열이 포함된 플라스미드로 형질전환된 세포주를 37 ℃ 이상의 온도 조건에서 배양하는 단계를 포함하는 방법에 비해 플라스미드 내 폴리 A 테일의 안정성이 증가한 것인, 방법.
- 제1항에 있어서, 상기 폴리 A 테일은 20 내지 400개의 아데닌(A)을 포함하는, 방법.
- 폴리 A 테일 (poly(A) tail) 을 포함하는 mRNA를 코딩하는 서열이 포함된 플라스미드로 형질전환된 세포주를 31 ℃ 이하 온도조건에서 배양하는 단계를 포함하는,mRNA 생산을 위한 플라스미드의 대량 생산방법.
- 폴리 A 테일 (poly(A) tail) 을 포함하는 mRNA를 코딩하는 서열이 포함된 플라스미드로 형질전환된 세포주를 31 ℃ 이하의 온도 조건으로 배양하는 단계; 및상기 세포주의 플라스미드를 주형으로 전사(transcription)를 수행하는 단계를 포함하는,폴리 A 테일을 포함하는 mRNA의 생산방법.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280056262.2A CN117836418A (zh) | 2021-08-17 | 2022-08-17 | 稳定保持聚a尾的方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2021-0108264 | 2021-08-17 | ||
KR20210108264 | 2021-08-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023022490A1 true WO2023022490A1 (ko) | 2023-02-23 |
Family
ID=85239582
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/012233 WO2023022490A1 (ko) | 2021-08-17 | 2022-08-17 | 폴리 a 테일을 안정적으로 유지하는 방법 |
Country Status (3)
Country | Link |
---|---|
KR (1) | KR20230026965A (ko) |
CN (1) | CN117836418A (ko) |
WO (1) | WO2023022490A1 (ko) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100323400A1 (en) * | 2003-07-01 | 2010-12-23 | Haskins Darin J | Compositions and Methods for Controlling Copy Number for a Broad Range of Plasmids and Uses Thereof |
WO2016005324A1 (en) * | 2014-07-11 | 2016-01-14 | Biontech Rna Pharmaceuticals Gmbh | Stabilization of poly(a) sequence encoding dna sequences |
-
2022
- 2022-08-17 CN CN202280056262.2A patent/CN117836418A/zh active Pending
- 2022-08-17 WO PCT/KR2022/012233 patent/WO2023022490A1/ko active Application Filing
- 2022-08-17 KR KR1020220102797A patent/KR20230026965A/ko not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100323400A1 (en) * | 2003-07-01 | 2010-12-23 | Haskins Darin J | Compositions and Methods for Controlling Copy Number for a Broad Range of Plasmids and Uses Thereof |
WO2016005324A1 (en) * | 2014-07-11 | 2016-01-14 | Biontech Rna Pharmaceuticals Gmbh | Stabilization of poly(a) sequence encoding dna sequences |
Non-Patent Citations (6)
Title |
---|
ACTA ALIMENTARIA, vol. 2, 2021, pages 180 - 188 |
GRIER ALEXANDRA E ET AL: "pEVL: A Linear Plasmid for Generating mRNA IVT Templates With Extended Encoded Poly(A) Sequences.", MOLECULAR THERAPY. NUCLEIC ACIDS 19 APR 2016, vol. 5, 19 April 2016 (2016-04-19), pages 1 - 10, XP002787530, DOI: 10.1038/mtna.2016.21 * |
MOL THER NUCLEIC ACIDS., vol. 26, 3 December 2021 (2021-12-03), pages 945 - 956 |
RNA, vol. 25, no. 4, April 2019 (2019-04-01), pages 507 - 518 |
TREPOTEC ZELJKA; GEIGER JOHANNES; PLANK CHRISTIAN; ANEJA MANISH K; RUDOLPH CARSTEN: "Segmented poly(A) tails significantly reduce recombination of plasmid DNA without affecting mRNA translation efficiency or half-life", RNA, COLD SPRING HARBOR LABORATORY PRESS, US, vol. 25, no. 4, 31 March 2019 (2019-03-31), US , pages 507 - 518, XP009517039, ISSN: 1355-8382, DOI: 10.1261/rna.069286.118 * |
TUDEK AGNIESZKA, KRAWCZYK PAWEŁ S., MROCZEK SEWERYN, TOMECKI RAFAŁ, TURTOLA MATTI, MATYLLA-KULIŃSKA KATARZYNA, JENSEN TORBEN HEICK: "Global view on the metabolism of RNA poly(A) tails in yeast Saccharomyces cerevisiae", NATURE COMMUNICATIONS, vol. 12, no. 1, XP093036347, DOI: 10.1038/s41467-021-25251-w * |
Also Published As
Publication number | Publication date |
---|---|
KR20230026965A (ko) | 2023-02-27 |
CN117836418A (zh) | 2024-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020175735A1 (ko) | 신규 프로모터 및 이를 이용한 퓨린 뉴클레오티드 제조방법 | |
WO2018124440A2 (ko) | 신규한 이소프로필말레이트 신타제 변이체 및 이를 이용한 l-류신의 생산 방법 | |
WO2019117399A1 (ko) | 신규 폴리펩타이드 및 이를 이용한 imp 생산방법 | |
WO2019117671A1 (ko) | 5'-이노신산을 생산하는 미생물 및 이를 이용한 5'-이노신산의 생산 방법 | |
WO2009125924A2 (ko) | 퓨트레신 고생성능을 가지는 변이 미생물 및 이를 이용한 퓨트레신의 제조방법 | |
WO2019004778A2 (ko) | 신규한 아스파토키나제 변이체 및 이를 이용한 l-아미노산의 제조방법 | |
WO2019190192A1 (ko) | 신규한 프로모터 및 이를 이용한 l-아미노산 생산 방법 | |
WO2019231159A1 (ko) | 변이형 호모세린 디하이드로게나제 및 이를 이용한 호모세린 또는 호모세린 유래 l-아미노산의 생산 방법 | |
WO2012018226A2 (ko) | 카다베린 고생성능을 가지는 변이 미생물 및 이를 이용한 카다베린의 제조방법 | |
WO2019147059A1 (ko) | L-아미노산을 생산하는 코리네박테리움 속 미생물 및 이를 이용한 l-아미노산의 생산방법 | |
WO2020130236A1 (ko) | 변이형 호모세린 디하이드로게나제 및 이를 이용한 호모세린 또는 호모세린 유래 l-아미노산의 생산 방법 | |
WO2014208970A1 (ko) | 트랜스케톨라아제 유전자 프로모터 변이체 및 이의 용도 | |
WO2021167414A1 (ko) | 퓨린 뉴클레오티드를 생산하는 미생물 및 이를 이용한 퓨린 뉴클레오티드의 생산방법 | |
WO2019135445A1 (ko) | 신규 폴리펩타이드 및 이를 이용한 imp 생산방법 | |
WO2021201653A1 (ko) | Crispr/cas9 시스템을 기반으로 한 유전체 편집 방법 및 이의 용도 | |
WO2016148490A1 (ko) | 피루브산 디하이드로게나아제 변이체, 이를 포함하는 미생물 및 이를 이용한 l-아미노산 생산 방법 | |
WO2019172702A1 (ko) | 신규한 프로모터 및 이를 이용한 l-아미노산 생산 방법 | |
WO2020196993A1 (ko) | 변이형 포스포리보실피로포스페이트 아미도트랜스퍼라아제 및 이를 이용한 퓨린 뉴클레오티드 제조방법 | |
WO2023022490A1 (ko) | 폴리 a 테일을 안정적으로 유지하는 방법 | |
WO2015163682A1 (ko) | 2,3-부탄디올의 생성능이 증강된 재조합 미생물 및 이를 이용한 2,3-부탄디올의 생산 방법 | |
WO2019004779A2 (ko) | 신규한 o-숙시닐 호모세린 트랜스퍼라제 변이체 및 이를 이용한 o-숙시닐 호모세린의 제조방법 | |
WO2022098191A1 (ko) | 하이드로겔화 핵산을 이용한 고분자량 단백질 생산용 원형 핵산 템플릿의 제조방법 및 고분자량 단백질 생산 시스템 | |
WO2019031804A9 (ko) | 목적 유전자 발현 조절을 위한 대장균 및 코리네박테리움 글루타미쿰 셔틀 벡터 | |
WO2022239953A1 (ko) | 3-메틸-2-옥소뷰타노에이트 하이드록시 메틸트랜스퍼라아제의 활성이 강화된 미생물, 및 이의 용도 | |
WO2019004780A2 (ko) | 신규한 o-숙시닐 호모세린 트랜스퍼라제 변이체 및 이를 이용한 o-숙시닐 호모세린의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22858727 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280056262.2 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022858727 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022858727 Country of ref document: EP Effective date: 20240318 |